Cell Impact AB Total Liabilities
Cell Impact AB total liabilities. Based on the latest financial reports, Cell Impact AB (CI) has total liabilities worth Skr29.21 Million SEK (≈ $3.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cell Impact AB (2008–2024)
Total liabilities of Cell Impact AB from 2008 to 2024. This chart illustrates how Cell Impact AB's total liabilities have evolved over time, based on quarterly financial data.
Cell Impact AB Competitors by Total Liabilities
The table below lists competitors of Cell Impact AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prostatype Genomics AB
ST:PROGEN
|
Sweden | Skr7.36 Million |
|
Lilium NV
NASDAQ:LILM
|
USA | $280.49 Million |
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
UK | GBX16.56 Million |
|
MEMIONTEC HOLDINGS LTD
F:8900
|
Germany | €25.07 Million |
|
SpectraCure AB
ST:SPEC
|
Sweden | Skr10.92 Million |
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
Germany | €280.97K |
|
Infinitum Copper Corp
V:INFI
|
Canada | CA$757.67K |
|
Panthera Resources PLC
LSE:PAT
|
UK | GBX1.06 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Cell Impact AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cell Impact AB total assets.
Liquidity & Leverage Metrics
Cell Impact AB Total Liabilities Ratios Explained
Cell Impact AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cell Impact AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cell Impact AB (2008–2024)
The table below shows the annual total liabilities of Cell Impact AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr42.16 Million ≈ $4.54 Million |
-46.33% |
| 2023-12-31 | Skr78.56 Million ≈ $8.45 Million |
+1.81% |
| 2022-12-31 | Skr77.17 Million ≈ $8.30 Million |
-19.70% |
| 2021-12-31 | Skr96.10 Million ≈ $10.34 Million |
+134.46% |
| 2020-12-31 | Skr40.99 Million ≈ $4.41 Million |
+215.67% |
| 2019-12-31 | Skr12.98 Million ≈ $1.40 Million |
-31.45% |
| 2018-12-31 | Skr18.94 Million ≈ $2.04 Million |
+192.67% |
| 2017-12-31 | Skr6.47 Million ≈ $696.49K |
-41.68% |
| 2016-12-31 | Skr11.10 Million ≈ $1.19 Million |
+108.17% |
| 2015-12-31 | Skr5.33 Million ≈ $573.65K |
+72.98% |
| 2014-12-31 | Skr3.08 Million ≈ $331.63K |
-5.38% |
| 2013-12-31 | Skr3.26 Million ≈ $350.50K |
-10.91% |
| 2012-12-31 | Skr3.66 Million ≈ $393.43K |
-38.66% |
| 2011-12-31 | Skr5.96 Million ≈ $641.40K |
-62.58% |
| 2010-12-31 | Skr15.93 Million ≈ $1.71 Million |
+318419.22% |
| 2009-12-31 | Skr5.00K ≈ $538.08 |
-62.09% |
| 2008-12-31 | Skr13.19K ≈ $1.42K |
-- |
About Cell Impact AB
Cell Impact AB (publ) manufactures and sells bipolar flow plates for hydrogen fuel cells and electrolyzers in the United States, Sweden, Other Europe, and Asia. The company offers production series of flow plates; design for manufacturing and other design services; tools and prototypes; local production; and leak testing, cleaning options, and advanced measurement instruments. The company was inc… Read more